Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Abstract
..
All quercetin studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   Meta Analysis       

Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike mutants with high viral infectivity

Pan et al., Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.10.029
Oct 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
Lower risk for ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Silico and In Vitro study of quercetin showing inhibition of SARS-CoV-2 for wildtype and 6 different variants. Molecular docking and dynamics simulation analyses showed that quercetin binds in a cavity at the spike-ACE2 interface, suggesting it may disrupt spike-ACE2 binding. The study tested 6 spike mutants predicted to have high ACE2 affinity. Pseudotyped viruses containing these mutant spikes were pre-treated with quercetin before infecting cells. Quercetin dose-dependently reduced infection with all variants tested.
Bioavailability. Quercetin has low bioavailability and studies typically use advanced formulations to improve bioavailability which may be required to reach therapeutic concentrations.
73 preclinical studies support the efficacy of quercetin for COVID-19:
45 In Silico studies1-45
22 In Vitro studies1,2,5,15,19,21,25,42,46-59
6 In Vivo animal studies5,19,52,55,60,61
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
Important missing comments or errors? Let us know.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Pan et al., 17 Oct 2023, China, peer-reviewed, 6 authors. Contact: liuliren@tmu.edu.cn, limin@mail.csu.edu.cn.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike mutants with high viral infectivity
Boyu Pan, Senbiao Fang, Liangjiao Wang, Zhanyu Pan, Min Li, Liren Liu
Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.10.029
The emergence of SARS-CoV-2-Spike mutants not only enhances viral infectivity but also lead to treatment failure. Gaining a comprehensive understanding of the molecular binding mode between the mutant SARS-CoV-2-Spike and human ACE2 receptor is crucial for therapeutic development against this virus. Building upon our previous predictions and verifications regarding heightened viral infectivity of six potential SARS-CoV-2-Spike mutants, this study aims to further investigate the potential disruption of the interaction between these mutants and ACE2 by quercetin, a Chinese herbal compound. Molecular docking and dynamics simulations results reveal that the binding sites of quercetin particularly enriched around a specific "cavity" at the interface of Spike/ACE2 complex, indicating a favorable region for quercetin to interfere with Spike/ACE2 interaction. Virus infection assay confirms that quercetin not only attenuates wild-type virus infectivity but also suppresses the infectivity of all six tested SARS-CoV-2-Spike mutants. Therefore, quercetin represents a promising therapeutic candidate against both wild-type and potential future variants of SARS-CoV-2 exhibiting high viral infectivity.
Author contributions Liren Liu and Min Li designed and supervised the study and finalized the manuscript. Boyu Pan, Senbiao Fang, Liangjiao Wang and Zhanyu Pan contributed to the study design, performed the molecular docking & molecular dynamics simulations analyses and biological experiments and drafted the manuscript. All the authors approved the version to be published. Author Statement We the undersigned declare that this manuscript entitled "Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike mutants with high viral infectivity" is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. Conflict of Interest Statement All the authors (Boyu Pan, Senbiao Fang, Liangjiao Wang, Zhanyu Pan, Min Li and Liren Liu) declare that they have no competing interests. Highlights: 1. Quercetin is mainly enriched in the cavity at the binding interface between Spike domain and the human ACE2 target.
References
Cosar, Karagulleoglu, Unal, Ince, Uncuoglu et al., SARS-CoV-2 mutations and their viral variants, Cytokine Growth Factor Rev
Fang, Zheng, Lei, Wang, Zheng et al., Key residues influencing binding affinities of 2019-nCoV with ACE2 in different species, Brief Bioinform
Harvey, Carabelli, Jackson, Gupta, Thomson et al., SARS-CoV-2 variants, spike mutations and immune escape, Nat Rev Microbiol
J O U R N A L P R E, None
Jamieson, Rasmussen, An update on COVID-19 and pregnancy, Am J Obstet Gynecol
Lan, Ge, Yu, Shan, Zhou et al., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature
Lei, Chen, Wu, Duan X Men, Small molecules in the treatment of COVID-19, Signal Transduct Tar
Li, Du, Liu, Li, Lv et al., Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals, ISME J
Maria, Stefania, Carmela, Idolo, Gian, Roles of flavonoids against coronavirus infection, Chem Biol Interact
Mcgrath, Xue, Dillen, Oldfield, Assad-Garcia et al., SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis, Proc Natl Acad Sci U S A
Miller Br 3rd, Td, Swails, Homeyer, Gohlke et al., MMPBSA.py: An Efficient Program for End-State Free Energy Calculations, J Chem Theory Comput
Pan, Fang, Zhang, Pan, Liu et al., Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor, Comput Struct Biotechnol J
Sonnleitner, Prelog, Sonnleitner, Hinterbichler, Halbfurter et al., Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host, Nat Commun
Wang, Yang, Zhao, Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery, Comput Struct Biotechnol J
Zhang, Li, Wu, Yu, Zhang et al., Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity, Emerg Microbes J o u r n a l P r e -p r o o f Infect
Zhou, Xu, Wang, Anashkina, Jiang, Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity, Brief Bioinform
{ 'indexed': { 'date-parts': [[2023, 10, 19]], 'date-time': '2023-10-19T04:50:45Z', 'timestamp': 1697691045763}, 'reference-count': 15, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 10, 1]], 'date-time': '2023-10-01T00:00:00Z', 'timestamp': 1696118400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 10, 16]], 'date-time': '2023-10-16T00:00:00Z', 'timestamp': 1697414400000}, 'content-version': 'vor', 'delay-in-days': 15, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': ['csbj.org', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 10]]}, 'DOI': '10.1016/j.csbj.2023.10.029', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 10, 17]], 'date-time': '2023-10-17T16:21:49Z', 'timestamp': 1697559709000}, 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike mutants with high ' 'viral infectivity', 'prefix': '10.1016', 'author': [ {'given': 'Boyu', 'family': 'Pan', 'sequence': 'first', 'affiliation': []}, {'given': 'Senbiao', 'family': 'Fang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liangjiao', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhanyu', 'family': 'Pan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Min', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7786-7874', 'authenticated-orcid': False, 'given': 'Liren', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.csbj.2023.10.029_bib1', 'doi-asserted-by': 'crossref', 'first-page': '177', 'DOI': '10.1016/j.ajog.2021.08.054', 'article-title': 'An update on COVID-19 and pregnancy', 'volume': '226', 'author': 'Jamieson', 'year': '2022', 'journal-title': 'Am J Obstet Gynecol'}, { 'key': '10.1016/j.csbj.2023.10.029_bib2', 'doi-asserted-by': 'crossref', 'first-page': '10', 'DOI': '10.1016/j.cytogfr.2021.06.001', 'article-title': 'SARS-CoV-2 mutations and their viral variants', 'volume': '63', 'author': 'Cosar', 'year': '2022', 'journal-title': 'Cytokine Growth Factor Rev'}, { 'key': '10.1016/j.csbj.2023.10.029_bib3', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/bib/bbab375', 'article-title': 'Impact of mutations in SARS-COV-2 spike on viral infectivity and ' 'antigenicity', 'volume': '23', 'author': 'Zhou', 'year': '2022', 'journal-title': 'Brief Bioinform'}, { 'key': '10.1016/j.csbj.2023.10.029_bib4', 'doi-asserted-by': 'crossref', 'DOI': '10.1073/pnas.2204717119', 'article-title': 'SARS-CoV-2 variant spike and accessory gene mutations alter ' 'pathogenesis', 'volume': '119', 'author': 'McGrath', 'year': '2022', 'journal-title': 'Proc Natl Acad Sci U S A'}, { 'key': '10.1016/j.csbj.2023.10.029_bib5', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41467-022-30163-4', 'article-title': 'Cumulative SARS-CoV-2 mutations and corresponding changes in immunity ' 'in an immunocompromised patient indicate viral evolution within the ' 'host', 'volume': '13', 'author': 'Sonnleitner', 'year': '2022', 'journal-title': 'Nat Commun'}, { 'key': '10.1016/j.csbj.2023.10.029_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1024', 'DOI': '10.1080/22221751.2022.2054369', 'article-title': 'Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic ' 'activation, cell-cell fusion, and neutralization sensitivity', 'volume': '11', 'author': 'Zhang', 'year': '2022', 'journal-title': 'Emerg Microbes Infect'}, { 'key': '10.1016/j.csbj.2023.10.029_bib7', 'doi-asserted-by': 'crossref', 'first-page': '215', 'DOI': '10.1038/s41586-020-2180-5', 'article-title': 'Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ' 'ACE2 receptor', 'volume': '581', 'author': 'Lan', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.csbj.2023.10.029_bib8', 'doi-asserted-by': 'crossref', 'first-page': '409', 'DOI': '10.1038/s41579-021-00573-0', 'article-title': 'SARS-CoV-2 variants, spike mutations and immune escape', 'volume': '19', 'author': 'Harvey', 'year': '2021', 'journal-title': 'Nat Rev Microbiol'}, { 'key': '10.1016/j.csbj.2023.10.029_bib9', 'doi-asserted-by': 'crossref', 'first-page': '3518', 'DOI': '10.1016/j.csbj.2020.11.010', 'article-title': 'Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin ' 'impair the binding of viral S-protein to ACE2 receptor', 'volume': '18', 'author': 'Pan', 'year': '2020', 'journal-title': 'Comput Struct Biotechnol J'}, { 'key': '10.1016/j.csbj.2023.10.029_bib10', 'doi-asserted-by': 'crossref', 'first-page': '963', 'DOI': '10.1093/bib/bbaa329', 'article-title': 'Key residues influencing binding affinities of 2019-nCoV with ACE2 in ' 'different species', 'volume': '22', 'author': 'Fang', 'year': '2021', 'journal-title': 'Brief Bioinform'}, { 'key': '10.1016/j.csbj.2023.10.029_bib11', 'doi-asserted-by': 'crossref', 'first-page': '3314', 'DOI': '10.1021/ct300418h', 'article-title': 'MMPBSA.py: An Efficient Program for End-State Free Energy Calculations', 'volume': '8', 'author': 'Miller', 'year': '2012', 'journal-title': 'J Chem Theory Comput'}, { 'key': '10.1016/j.csbj.2023.10.029_bib12', 'doi-asserted-by': 'crossref', 'first-page': '549', 'DOI': '10.1038/s41396-023-01368-2', 'article-title': 'Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across ' 'mammals', 'volume': '17', 'author': 'Li', 'year': '2023', 'journal-title': 'ISME J'}, { 'key': '10.1016/j.csbj.2023.10.029_bib13', 'article-title': 'Roles of flavonoids against coronavirus infection', 'volume': '328', 'author': 'Maria', 'year': '2020', 'journal-title': 'Chem Biol Interact'}, { 'key': '10.1016/j.csbj.2023.10.029_bib14', 'doi-asserted-by': 'crossref', 'first-page': '4684', 'DOI': '10.1016/j.csbj.2021.08.029', 'article-title': 'Co-crystallization and structure determination: An effective direction ' 'for anti-SARS-CoV-2 drug discovery', 'volume': '19', 'author': 'Wang', 'year': '2021', 'journal-title': 'Comput Struct Biotechnol J'}, { 'key': '10.1016/j.csbj.2023.10.029_bib15', 'article-title': 'Small molecules in the treatment of COVID-19', 'volume': '7', 'author': 'Lei', 'year': '2022', 'journal-title': 'Signal Transduct Tar'}], 'container-title': 'Computational and Structural Biotechnology Journal', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2001037023003860?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2001037023003860?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 10, 18]], 'date-time': '2023-10-18T22:22:50Z', 'timestamp': 1697667770000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2001037023003860'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 10]]}, 'references-count': 15, 'alternative-id': ['S2001037023003860'], 'URL': 'http://dx.doi.org/10.1016/j.csbj.2023.10.029', 'relation': {}, 'ISSN': ['2001-0370'], 'subject': [ 'Computer Science Applications', 'Genetics', 'Biochemistry', 'Structural Biology', 'Biophysics', 'Biotechnology'], 'container-title-short': 'Computational and Structural Biotechnology Journal', 'published': {'date-parts': [[2023, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike ' 'mutants with high viral infectivity', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Computational and Structural Biotechnology Journal', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.csbj.2023.10.029', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 The Authors. Published by Elsevier B.V. on behalf of Research Network of ' 'Computational and Structural Biotechnology.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0